GrowthCurve Capital, a private equity firm based in New York, has made a majority investment in TailorMed, an Israeli-founded company whose software helps patients in the United States get and pay for their medications. TailorMed announced the deal on November 2, 2026.
The companies did not disclose the price or the size of the stake. Calcalist reported that the deal is worth about $250 million, and Globes put the company's valuation at the same figure. Both papers said most of TailorMed's existing shareholders will sell their holdings, making the deal an exit for the bulk of its venture investors.
TailorMed will keep operating under its current management team, led by co-founder and chief executive Srulik Dvorsky, and will keep its development center in Tel Aviv, Globes reported. Leerink Partners and TripleTree advised TailorMed on the transaction.
What TailorMed built
Dvorsky and Adam Siton founded TailorMed in 2016 after family experiences with serious illness, according to HIT Consultant. It started as software for financial navigation, helping hospitals find assistance for patients facing large bills, and now calls itself a medication access platform covering access, affordability, adherence and ongoing care.
The product targets patients in oncology, rare disease and chronic specialty care, where drug costs are high and many patients drop off treatment. HIT Consultant described several layers: TailorMed Core reads electronic health record data, insurance benefits and treatment plans to flag patients at risk early; TailorMed Connect & Complete automates enrolment and paperwork for grants, co-pay assistance, subsidies and free drug programs; and TailorMed Amplify & Alliance links health systems with drug makers for co-pay cards and support services inside the clinical workflow.
By the company's count, its network includes more than 950 hospitals, 4,700 clinics, 3,100 pharmacies and 6,000 public and private assistance programs, about 100 of them sponsored by pharmaceutical companies. It says it has supported more than 75 million patients and secured more than $7.4 billion in financial assistance since 2020. Globes reported that Walgreens is among the pharmacies it works with.
“We are thrilled to embark on this new chapter with GrowthCurve.”
Why GrowthCurve is buying
GrowthCurve describes itself as a firm that grows middle-market companies by putting AI to work, investing in technology and information services, healthcare and financial services. It said it would help TailorMed scale its AI-enabled software and sell more widely to health systems, outpatient clinics, retail and specialty pharmacies and life sciences companies.
Robert Thwaites, a director at GrowthCurve, told Globes that TailorMed has the largest and most diverse network in the patient financial assistance space. Dvorsky told the paper that the company's real advantage is not its AI or its data but the network effect of connecting so many providers, pharmacies and programs.
With the new owner's backing, TailorMed plans to acquire or merge with other companies in its sector, Globes and Calcalist reported. Dvorsky told Calcalist that the company would serve as the anchor for that platform, and that the buyer sees it as having the potential to establish an entirely new category.
The founders and the funding
Dvorsky was previously vice president of research and development at medical device company Brainsgate, and Siton, the chief technology officer, headed the mobile division at Any.do, according to Globes. Dvorsky moved to the United States four years ago to run the company there.
TailorMed raised about $60 million, according to both Israeli papers. It started in the Sanara Ventures incubator, and Globes and Calcalist list backers including Triventures, Accelmed, Bridges Israel, Discount Capital, Allumia Ventures (formerly Providence Ventures), Almeda Ventures, Samsung Next, the American Cancer Society's BrightEdge, the Citi Impact Fund, OSF Ventures and Windham Ventures. Almeda Ventures, which is listed in Tel Aviv, holds about 3% after investing $2.4 million, Globes reported.
The company employs about 120 to 130 people, roughly 50 to 60 of them in Israel; Calcalist and Globes gave slightly different figures. Calcalist said employees are expected to stay after the deal closes.
Another Israeli health tech exit
The sale comes after a busy October for Israeli technology exits, which Calcalist tallied from Proofpoint's $6.3 billion purchase of Varonis to small deals for startups with a handful of employees. TailorMed went to a financial buyer rather than a strategic one, and keeps its own management and brand.
Michal Geva of Triventures, one of the early investors, spoke to Calcalist about the founders and what she called one of the defining traits of Israeli entrepreneurs. Dvorsky said in the company's announcement that GrowthCurve shares TailorMed's commitment to its mission and brings the experience and strategic support the company needs. "We are thrilled to embark on this new chapter with GrowthCurve," he said.
